Indianapolis-based Eli Lilly's expansion into Bristol will focus on manufacturing injectable medications, device assembly and ...
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
Given the strong demand expected for Eli Lilly's (NYSE:LLY) weight loss treatment Zepbound (tirzepatide) in the UK, the ...